Home

Matthew Ronsheim

CIK 1824386 · See Remarks · last filed 2024-05-21

Matthew Ronsheim is a corporate insider who has filed 10 SEC Form 4 insider transactions across 2 companies since 2021. The most recent filing shows the insider had shares withheld for taxes covering $4.3K of INVA on May 21, 2024. Across all open-market trades the lifetime net is −$12.0K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $836.9K across reported positions. 5 SEC filings were submitted jointly with Innoviva, Inc.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$836.9K

Companies

2

Total Filings

10

Lifetime Open-Market Net

-$12.0K

Filer Profile

Reported Address
35 GATEHOUSE DRIVE
WALTHAM, MA 02451
Related Filers
Innoviva, Inc. — 5 joint filings, latest 2024-05-21
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
INVA See Remarks 40,510 $20.66 $836.9K $0 4 2024-05-21
Entasis Therapeutics Holdings Inc. (ETTX) Delisted Chief of Pharma Sciences & MFG 0 $2.19 $0 -$12.0K 6 2022-07-11

Recent Filings

10 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2024-05-21 INVA Tax (F) −268 -$4.3K EDGAR
2024-03-07 INVA Grant (A) +12,768 $190.0K EDGAR
2024-02-22 INVA Tax (F) −807 -$12.8K EDGAR
2024-01-22 INVA Mixed −1,600 -$25.7K EDGAR
2022-07-11 Entasis Therapeutics Holdings Inc. (ETTX) Delisted Mixed −167,572 -$38.7K EDGAR
2022-02-15 Entasis Therapeutics Holdings Inc. (ETTX) Delisted Mixed — $0 EDGAR
2022-01-19 Entasis Therapeutics Holdings Inc. (ETTX) Delisted Grant (A) +125,000 $0 EDGAR
2021-11-03 Entasis Therapeutics Holdings Inc. (ETTX) Delisted Tax (F) −3,669 -$10.8K EDGAR
2021-10-20 Entasis Therapeutics Holdings Inc. (ETTX) Delisted Mixed +21,241 -$12.0K EDGAR
2021-01-19 Entasis Therapeutics Holdings Inc. (ETTX) Delisted Grant (A) +25,000 $0 EDGAR
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.